Skip to Content

Resistance Data Human Medicine

Interactive Database Query

Inspect the most relevant resistance data of Switzerland in a tabular view and customize the query according to your preferences.

Close by ANRESIS

INterface For Empirical antimicrobial ChemoTherapy

INFECT is an interactive web application which is directed particularly towards health professionals. It gives a fast and intuitive access to ANRESIS resistance data and connects them with the latest national treatment guidelines. The INFECT project has been developed with support from the Federal Office of Public Health and the Institute for Infectious Diseases Bern.


MIC / DD Distributions
MIC / DD Distributions

Coming soon


Carbapenem Resistance

Carbapenem-resistant Enterobacterales

Although on a relatively low-level, numbers of carbapenem-resistant Enterobacterales have constantly increased during the last years.

Carbapenem-resistant Enterobacterales (CRE)

Carbapenems are broad spectrum antibiotics, used for severe infections with some multidrug-resistant microorganisms, in particular extended-spectrum betalactamase-producing Enterobacterales. Resistance to this class of reserve antibiotics  is therefore crucial to survey. ANRESIS analyses carbapenem resistance in Enterobacterales continuously and publishes data on this web-site.

Carbapenem non-susceptibility can be mediated via different mechanisms such as permeability defects, efflux pumps or by the production of carbapenemase enzymes. The resistance mechanism cannot be predicted from the resistance test alone, genomic analyses are needed. Due to their multiresistance and their rapid spread a separate focus is laid on the carbapenemase-producing enterobacterales (see next section).

Temporal Course of CRE in Switzerland

CRE Distribution of Microorganisms

Carbapenemase Producers

Enterobacterales which are in possession of carbapenemase enzymes (the so-called carbapenemase-producing Enterobacterales or CPE) are particularly resistant to numerous other antibiotic classes than carbapenems. Due to this multresistance and due to their rapid spread, they pose a particular threat. The reporting of CPE has therefore been declared as mandatory by the Swiss government on January 2017 and since January 2019 all CPE isolates must be sent to the National Reference Centre for Emerging Antibiotic Resistance (NARA) for a detailed analysis of the resistance mechanisms and for early detection of outbreaks. An overview on CPE was published in the Swiss Antibiotic Resistance Report 2020.

CPE are classified according to the amino acid sequence similarities of their carbapenemases. The most prevalent CPE genotypes in Switzerland are currently the OXA-48-types and KPCs. ANRESIS publishes the actual CPE data quarterly on this Website. Of note, these data cannot be compared directly to data before 2019 due to a change in the reporting system. All of the following graphs are based on data from NARA.

Regional Distribution of CPE in Switzerland





Back to top